Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsN/A

Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke

Sponsor: Cwm Taf University Health Board (NHS)

NCT ID: NCT05645081

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Not specified by the sponsor
How long the study runs
Study runs about 71 months (dates as stated)
About the drug or intervention
Not specified by the sponsor
Patient visit burden
Not specified by the sponsor
Type of study
Observing health over time
Ages
18 Years and over
Who
All
Number of participants
360
Started
2021-10-01
Last checked
2024-02

Plain English Summary

What is this study?

  • • Testing a new treatment for stroke, ischemic
  • • Clinical study - 360 participants
  • • Annually 100,000 strokes occur, placing stroke as the largest cause of disability in the UK

Who can take part?

  • • Ages 18 Years and over
  • • Diagnosed with stroke, ischemic

Where?

  • • Merthyr Tydfil - Prince Charles Hospital

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

Annually 100,000 strokes occur, placing stroke as the largest cause of disability in the UK. 90% of strokes are preventable, leading to national focus on programmes including "The National Stroke Programme" to act on preventing, treating, and improving post-stroke care. Importantly, over 25% of ischaemic stroke sufferers have previously had a Transient Ischaemic Attack (TIA), which presents the biggest concern for TIA patients. There are no measures which reliably identify TIA patients most likely to suffer a stroke. Novel biomarkers for predicting stroke are key to addressing this problem. The PREDICT-EV study aims to screen 300 TIA patients and follow them over 12-months. The investigators will determine if a novel biomarker we've identified to increase thrombotic risk (endothelial derived extracellular vesicles) and the resulting increased prothrombin time is associated with patients at highest risk of stroke.

Stroke, IschemicTransient Ischemic AttackCoagulation Disorder

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years and over
  • Who can join: All genders

What the study is looking for

  • ✓The inclusion criteria for phase 1 (initial patient recruitment) will be:
  • ✓TIA confirmed patient has been prescribed antiplatelet drugs or anticoagulants.
  • ✓Patients must be aged \> 18 years.
  • ✓Patients are taking an ordinary diet by mouth.
  • ✓The inclusion criteria for phase 2 (patient representing with stroke) will be:
See the full criteria
The inclusion criteria for phase 1 (initial patient recruitment) will be: 1. Patients with or without diagnosis of TIA made by a physician working in stroke medicine, sufficiently so to start post-TIA care or so that no further investigation is thought necessary to confirm or refute the diagnosis. 2. TIA confirmed patient has been prescribed antiplatelet drugs or anticoagulants. 3. Patients must be aged \> 18 years. 4. Patients are taking an ordinary diet by mouth. The inclusion criteria for phase 2 (patient representing with stroke) will be: 1. Radiological evidence, on CT and/or MR imaging of the brain of cerebral infarction, with or without secondary haemorrhage. 2. The underlying mechanism of cerebral infarction is embolic from a cardiac source (e.g. atrial fibrillation), atherothromboembolic (from aorta or other large vessels in the neck) or in-situ thrombosis. No further investigations are thought necessary to confirm or refute the diagnosis. 3. No further investigations are thought necessary to confirm or refute the diagnosis. 4. Patients must be aged \>18 years. 5. Patients must not be pregnant or breast feeding. 6. Patients are taking an ordinary diet by mouth. Exclusion Criteria The Exclusion criteria for phase 1 (initial patient recruitment) will be: 1. Inability to give consent. 2. Inability to feed by mouth. 3. Short life expectancy. 4. Pregnancy or breastfeeding. 5. Symptoms are readily explained by medical problems not involving focal cerebral ischaemia. The Exclusion criteria for phase 2 (patient representing with stroke) will be: 1. Patients who have not previously given consent for follow up blood sampling. 2. Patients who are unable to feed by mouth. 3. Patients in whom life expectancy is short. 4. Patient is pregnant or breast feeding.

Where Is This Study? (1 UK site)

Prince Charles Hospital

Merthyr Tydfil CF479DT, United Kingdom

Recruiting
Site contact (verified)

How to Get in Touch

Jessica Williams, PhD

Sponsor contact

CONTACT

02920417077 jwilliams3@cardiffmet.ac.uk
Data sourced from ClinicalTrials.gov · Last verified: 2024-02